Ming Shing Group Holdings Limited Announces Resignation of Director and Addition to Board of Directors
Globenewswire· 2025-11-07 00:50
Hong Kong, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Ming Shing Group Holdings Limited (the “Company” or “Ming Shing”) (NASDAQ: MSW), a Hong Kong-based company mainly engaged in wet trades works whose mission it is to become the leading wet trades works service provider in Hong Kong, announces a significant update in its board of directors (the “Board of Directors”). Ming Shing announces the resignation of Yu Yuan as an independent director. Mr. Yuan has indicated his resignation is for personal reasons and not due ...
Disclosure Of Trading In Own Shares For October 2025
Globenewswire· 2025-11-07 00:45
Disclosure Of Trading In Own SharesFor October 2025 Clichy, France – November 06, 2025 In compliance with general regulation on share buy-backs, Société BIC declares below the transactions made on its own shares for October 2025: DateNumber of sharesAverage weighted price in €Amount in €02/10/20251653.0000848.0002/10/20258,00053.1000424,800.00<td style="width:12.39%;;te ...
Akwel: Nine-Month Revenue Down -3.6%
Globenewswire· 2025-11-07 00:45
2025年前九个月财务表现 - 2025年前九个月公司公布合并营收为7.307亿欧元,较2024年同期下降3.6% [2] - 2025年第三季度合并营收为2.201亿欧元,报告业务下降3.9%,按固定范围和汇率计算下降2.0% [4] - 第三季度外汇汇率产生440万欧元的负面影响,主要受美元影响 [4] - 公司净现金状况强劲,截至2025年9月30日,合并净现金(不包括租赁负债影响)为1.689亿欧元,较2025年6月30日增加1960万欧元 [6] 分季度及分地区营收分析 - 2025年第一季度营收2.556亿欧元,同比下降3.0% [3] - 2025年第二季度营收2.55亿欧元,同比下降3.9% [3] - 2025年第三季度营收2.201亿欧元,同比下降3.9% [3] - 按地理生产区域划分,前九个月累计营收为:欧洲、中东和非洲地区4.913亿欧元(下降1.6%),美洲地区2.148亿欧元(下降6.7%),亚洲地区2460万欧元(下降13.6%) [9] 产品线表现 - 前九个月产品与功能营收下降1.4%至7.126亿欧元 [5] - 增长的产品线包括:冷却系统(增长1.6%)、净化系统(增长7.0%)、燃油系统(增长5.1%)和机油系统(增长5.7%) [5] - 下滑的产品线包括:空气系统(下降19.1%)、机械系统(下降4.7%)和控制系统(下降5.5%) [5] - 工具业务录得营收1100万欧元 [5] 2025年及2026年展望 - 公司此前预计2025年业务下滑幅度将低于上年,部分原因是SCR油箱生产停产推迟至2026年 [7] - 公司目前预计2026年合并营收将出现两位数下滑 [8] - 2026年展望悲观主要反映SCR油箱预期销量下降,以及所有产品线面临的不利前景 [8] - 不利前景包括欧美多个电动汽车生产项目的取消、推迟或严重延迟启动,以及一些内燃机车辆流体和机械项目的终止 [10] - 公司还将面临市场低迷、电动汽车发展缓慢、限制性或不明朗的海关做法、中国竞争对手的压力以及需要控制成本等挑战 [11]
Euronext announces launch of a share repurchase programme of €250 million
Globenewswire· 2025-11-07 00:45
Euronext announces launch of a share repurchase programme of €250 million Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 6 November 2025 – Euronext today announces a share repurchase programme (the ‘Programme’) for a maximum amount of €250 million. This Programme demonstrates Euronext’s proactive approach to capital allocation, the Group’s strong deleveraging path, and management’s confidence in the growth prospects of the Group. The Programme fully preserves the Group’s credit rating, finan ...
Euronext publishes Q3 2025 results and announces a share repurchase programme
Globenewswire· 2025-11-07 00:45
Euronext publishes Q3 2025 results and announces a share repurchase programme Euronext has delivered the sixth consecutive quarter of double-digit growth, driven by the expansion of non-volume-related businesses, resilient trading and clearing revenues and continued cost discipline. Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 6 November 2025 – Euronext, the leading European capital market infrastructure, today publishes its results for the third quarter of 2025. Q3 2025 revenue and income ...
Disclosure of total number of voting rights and number of shares forming the capital as of October 31, 2025
Globenewswire· 2025-11-07 00:45
Disclosure of total number of voting rights andnumber of shares forming the capitalas of October 31, 2025 Clichy, France – November 06, 2025 Article L 233-8-II of the French “Code de Commerce” and Article 223-16 of the General Regulations of the French “Autorité des Marchés Financiers”. As of October 31, 2025, the total number of issued shares of SOCIÉTÉ BIC is 41,621,162 shares, representing:- 58,357,733 voting rights,- 57,750,137 voting rights excluding shares without voting rights Contacts Brice ParisVP ...
Akwel: Nine-month revenue down -3.6%
Globenewswire· 2025-11-07 00:45
Champfromier — Thursday, November 6, 2025 NINE-MONTH REVENUE DOWN -3.6% AKWEL (FR0000053027, AKW, PEA-eligible), parts and systems manufacturer for the automotive and heavy-vehicle industry, specialist in fluid management, mechanisms and structural parts for electric vehicles, has recorded, over the first 9 months of 2025, a published consolidated revenue of €730.7M. Consolidated revenue (from January 1 to September 30, 2025) in €m — unaudited20252024VariationPCC variation (1)1st quarter255.6263.5-3.0%-4.0 ...
Banijay Group: 9M 2025 results
Globenewswire· 2025-11-07 00:45
Press Release Paris, 6 November 2025 2025 First Nine Months Results REVENUE UP 4.0% IN 9M25LIVE EXPERIENCES DRIVING GROWTH AT BANIJAY ENTERTAINMENT & LIVESTRONG PERFORMANCE AT BANIJAY GAMING, EVEN WITH HIGH 2024 COMPARISON & ADVERSE SPORTS RESULTS IN SEPTEMBER ADJUSTED EBITDA UP 9.8% IN 9M25 REINFORCING LEADERSHIP IN SPORTS BETTING AND ONLINE GAMING WITH TIPICO GROUP ACQUISITION 9M 2025 FINANCIAL HIGHLIGHTS1 Revenue up +4.0% to €3,224m in 9M 2025Adjusted EBITDA up +9.8% to €597m, Adjusted EBITDA margin up ...
JCDecaux : Q3 2025 trading update
Globenewswire· 2025-11-07 00:41
Q3 2025 trading update Digital continues to drive organic revenue growth Paris, November 6th, 2025 Robust underlying revenue growth €926.1m in revenue in Q3 2025 -2.3% reported revenue growth-0.9% organic revenue growth, slightly above our expectationsc.+3% underlying organic revenue growth, i.e. excluding c.410bp comparison impact due to the 2024 Paris Olympic & Paralympic Games and UEFA Euro+7.6% organic digital revenue growth Guidance for Q4 2025: organic revenue growth expected around flat, includin ...
Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025
Globenewswire· 2025-11-07 00:31
Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025 Compelling kidney function data from VIVIAD Phase 2b study presented in late-breaking poster at ASN kidney week, the world’s premier nephrology meetingVIVIAD analyses continue to support varoglutamstat’s potential in kidney disease, and consistently provide further evidence for a beneficial impact on kidney function based on its proposed mechanism of action Halle (Saale) / ...